Abstract
Limited pharmacological options exist for patients with resistant hypertension (RH). Sympathetic renal denervation therapy (RDN) is a novel approach which has been evaluated in multiple small studies. We sought to determine the current effectiveness and safety of RDN on RH. We performed a
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
